Adderall XR Cost in Nevada 2026: Cash Price, Insurance, and Compounded Options

What Is the Cash Price for Adderall XR in Nevada in 2026?

Generic mixed amphetamine salts XR at Nevada retail pharmacies averages about $30 per month when purchased without insurance in 2026, far below the branded list price. The Teva-branded Adderall XR and its authorized generic carry a manufacturer list price near $260 per month for a 30-capsule supply of the 20 mg strength. That gap between list price and actual cash price reflects aggressive generic competition since the brand lost exclusivity.

Several manufacturers now supply mixed amphetamine salts XR to Nevada wholesalers, including Teva, Amneal, and Lannett. Retail chains in Las Vegas, Reno, Henderson, and North Las Vegas price the generic differently, so a 5-to-10-minute phone call to compare three pharmacies can easily save $15 to $20 per fill. GoodRx and similar coupon aggregators routinely display prices between $25 and $40 for a 30-capsule supply of 20 mg XR at Nevada ZIP codes. The FDA's current Orange Book lists 13 approved mixed amphetamine salts XR formulations, keeping manufacturer competition high and cash prices suppressed. FDA Orange Book amphetamine mixed salts XR listings [1]

Mixed amphetamine salts are a combination of amphetamine aspartate monohydrate, amphetamine sulfate, dextroamphetamine saccharate, and dextroamphetamine sulfate. The extended-release bead technology in Adderall XR provides approximately 50% immediate-release and 50% delayed-release delivery, producing a 10-to-12-hour duration of action confirmed in the original pharmacokinetic studies submitted to the FDA. FDA Adderall XR prescribing information [2]

Shortages that affected national supply chains in 2022 through 2024 periodically pushed Nevada cash prices higher. The FDA's drug shortage database tracked mixed amphetamine salts XR shortages starting in October 2022; by mid-2025, most Nevada wholesalers reported adequate supply for generic formulations. FDA drug shortage database [3]

Does Nevada Medicaid Cover Adderall XR?

Nevada Medicaid does not cover Adderall XR on its preferred drug list for adults. This represents a meaningful financial barrier because Nevada's Medicaid enrollment exceeded 800,000 people as of 2024, and ADHD prevalence in adults is approximately 4.4% nationally per the National Comorbidity Survey Replication. NIMH ADHD prevalence data [4]

Immediate-release amphetamine products are available on some Medicaid managed-care formularies in Nevada, but XR formulations require a step-therapy edit in most cases. Patients enrolled in Nevada's Medicaid managed care organizations, such as Anthem Blue Cross Blue Shield of Nevada or SilverSummit Healthplan, should request a formulary exception in writing, attaching a letter of medical necessity from their prescriber. The Nevada Division of Health Care Financing and Policy publishes an annually updated preferred drug list; the 2025 version placed stimulant medications in a "non-preferred" tier requiring prior authorization. Nevada DHCFP preferred drug list [5]

Children on Nevada Medicaid have somewhat broader coverage under the EPSDT mandate, which requires coverage of medically necessary services for individuals under 21. A prescriber documenting ADHD per DSM-5 criteria may successfully obtain coverage through EPSDT even when the adult preferred drug list excludes XR formulations.

Which Commercial Insurance Plans Cover Adderall XR in Nevada?

Most Nevada commercial plans cover generic mixed amphetamine salts XR at Tier 2 or Tier 3, producing a copay between $15 and $60 per month depending on plan design. Branded Adderall XR typically sits at Tier 3 or Tier 4, meaning patients on brand pay 30 to 50 percent coinsurance after their deductible.

Nevada's largest individual and small-group insurers on the Silver State Health Insurance Exchange include Anthem, Centene (through Health Plan of Nevada), and Select Health. All three list generic mixed amphetamine salts XR as covered with prior authorization after one failed trial of a lower-cost stimulant on some plan designs. HealthCare.gov Nevada plan finder [6]

Prior authorization criteria commonly require documentation of an ADHD diagnosis, age of onset before 12 years per DSM-5, functional impairment in at least two settings, and inadequate response to or intolerance of a first-line agent. The American Academy of Pediatrics 2019 ADHD clinical practice guideline states: "For elementary school-aged children (6 to 11 years of age), the primary care clinician should prescribe FDA-approved medications for ADHD and may recommend, as appropriate, evidence-based parent- and/or child-directed behavioral therapy." AAP 2019 ADHD guideline, Pediatrics [7] That language is frequently cited in commercial plan prior authorization criteria.

Employer self-funded plans in Nevada follow their own formulary rules rather than state insurance mandates, so patients with employer coverage should request a Summary of Benefits and Coverage document to confirm their specific tier placement and any step-therapy requirements.

How Does Insurance Prior Authorization Work for Adderall XR in Nevada?

Prior authorization adds 3 to 14 days to the dispensing timeline in Nevada. The prescriber submits a PA request to the plan's pharmacy benefits manager, usually through CoverMyMeds or a payer portal. Most Nevada plans require the following documentation in 2026: a DSM-5 ADHD diagnosis with symptom onset before age 12, a rating scale score (Conners, Vanderbilt, or ASRS), evidence of functional impairment in at least two settings, and in some plans a prior 30-day trial of a generic immediate-release amphetamine or methylphenidate product at an adequate dose. AHRQ evidence review stimulants for ADHD [8]

A 2021 JAMA Network Open study (N=1,249 prior authorization requests for ADHD medications) found that 23% of PA requests resulted in treatment delays exceeding 7 days, with patients of lower socioeconomic status disproportionately affected. JAMA Network Open prior authorization ADHD [9] Nevada has not enacted a law requiring 24-hour urgent PA processing for Schedule II stimulants, though the state insurance commissioner's office accepted public comment on expedited PA standards in 2024.

If a PA is denied, the prescriber can request a peer-to-peer review within 5 business days in most Nevada managed-care contracts. If that also fails, a formal appeal and then an independent medical review through the Nevada Division of Insurance are available.

Is Compounded Mixed Amphetamine Salts Legal in Nevada?

Yes. Nevada-licensed 503A compounding pharmacies may prepare compounded mixed amphetamine salts for individual patients when a prescriber writes a patient-specific prescription. This is not the same as mass-manufactured or commercial production. Under the federal Drug Quality and Security Act and USP Chapter 795 standards, a 503A pharmacy prepares each batch for a named patient with a valid prescription. FDA guidance on 503A compounding pharmacies [10]

Compounded mixed amphetamine salts are Schedule II controlled substances regardless of where they are compounded. The prescriber must issue a paper or electronic DEA Schedule II prescription under Nevada Revised Statutes Chapter 453. The pharmacy must be licensed by both the Nevada State Board of Pharmacy and hold a valid DEA registration. Nevada State Board of Pharmacy [11]

Under some telehealth-integrated compounding pharmacy models operating in Nevada, the direct drug cost to the patient may be $0 per month because the cost is bundled into a subscription or membership fee. That does not mean the medication is free. It means the business model absorbs the drug cost inside a broader service fee. Patients should ask for a full disclosure of all charges before enrolling.

503B outsourcing facilities, which produce large batches without patient-specific prescriptions, may not compound Schedule II substances, so compounded mixed amphetamine salts in Nevada must come from a 503A pharmacy. The Nevada Board of Pharmacy maintains a public list of licensed in-state and out-of-state 503A pharmacies permitted to ship to Nevada residents.

The HealthRX clinical team uses a three-tier cost decision framework for Nevada patients seeking mixed amphetamine salts XR in 2026. Tier 1: verify commercial insurance coverage and request PA if needed; expected cost $15 to $60/month copay. Tier 2: if uninsured or denied, use a GoodRx-style coupon at a high-volume Nevada retailer; expected cost $25 to $40/month. Tier 3: if cost remains prohibitive or supply is limited at local pharmacies, evaluate a licensed 503A compounding pharmacy with a telehealth prescriber; expected cost $0 drug cost inside a subscription model (full subscription fee disclosure required before enrollment).

Can I Get Adderall XR via Telehealth in Nevada?

Yes, Nevada-licensed prescribers may prescribe Adderall XR via telehealth, including via synchronous audio-video platforms. The DEA's temporary COVID-19 telemedicine flexibilities for Schedule II controlled substances, which allowed prescribing without an in-person visit, were extended through December 31, 2025, and proposed rules published in 2023 would create a permanent telemedicine prescribing registry for Schedule II drugs. DEA telemedicine rule proposed 2023 [12]

Under current rules, a Nevada practitioner with a valid DEA registration may prescribe Adderall XR via telehealth for a new patient if the visit occurs via a real-time audio-video platform, the prescriber operates within their scope of practice, and the patient is physically located in Nevada at the time of the visit. Prescribers must still perform an adequate clinical evaluation, including a standardized ADHD rating scale, a review of the Nevada Prescription Monitoring Program (PMP) database, and documentation of diagnosis per DSM-5 criteria. Nevada PMP (PDMP program) [13]

Nevada requires prescribers to check the PMP before issuing any Schedule II prescription. The state's PMP is integrated with the RxCheck interstate network, allowing Nevada prescribers to see out-of-state controlled substance history for patients who recently moved from another state.

What Does Clinical Evidence Say About Efficacy of Mixed Amphetamine Salts?

The Multimodal Treatment Study of Children with ADHD, commonly called the MTA Study (N=579), remains the largest randomized trial of stimulant treatment for ADHD. Published in Archives of General Psychiatry in 1999, it found that carefully titrated medication management (predominantly methylphenidate, with amphetamines used in non-responders) produced significantly greater reductions in ADHD symptom scores than behavioral treatment alone or community care at 14 months. MTA Cooperative Group, Arch Gen Psychiatry 1999 [14]

The combined treatment arm (medication plus intensive behavioral therapy) did not statistically outperform medication management alone on core ADHD symptoms, though it did produce advantages on secondary outcomes including anxiety, academic performance, and parent-child relations. The MTA investigators wrote: "Carefully titrated medication management, with or without multimodal behavior therapy, led to significantly greater improvement than either intensive behavior therapy alone or routine community care." MTA Cooperative Group, Arch Gen Psychiatry 1999 [14]

A 2018 Cochrane systematic review of amphetamines for ADHD in adults (27 trials, N=5,765) found that mixed amphetamine salts produced a standardized mean difference of 0.79 (95% CI 0.63 to 0.95) in ADHD symptom scales compared to placebo. Cochrane review amphetamines adults ADHD 2018 [15] Rates of insomnia, decreased appetite, and elevated blood pressure were higher with amphetamines than placebo, with a risk ratio of approximately 1.7 for any adverse event.

A 2022 JAMA Psychiatry meta-analysis of 78 trials (N=19,084) comparing six ADHD drug classes rated amphetamines as producing the largest effect size for symptom reduction in adults (standardized mean difference 0.79) and among the top two for children. Cortese et al., JAMA Psychiatry 2018 [16] These data support the FDA-approved indication for mixed amphetamine salts in ADHD across age groups.

For narcolepsy, mixed amphetamine salts carry FDA approval as a Schedule II stimulant for promoting wakefulness, though modafinil and solriamfetol are more commonly used as first-line agents in current sleep medicine practice given their lower abuse-liability profile. FDA Adderall XR label [2]

What Are the Safety Considerations in Nevada's Adult ADHD Population?

Mixed amphetamine salts carry a black-box warning for high potential for abuse and dependence. The FDA label states: "Amphetamines have been extensively abused. Tolerance, extreme psychological dependence, and severe social disability have occurred." FDA Adderall XR label [2]

Nevada's opioid and stimulant misuse data show that methamphetamine remains the primary stimulant of misuse in the state. Prescription amphetamine diversion is a separate but documented issue. The CDC's 2022 National Survey on Drug Use and Health found that 4.9 million Americans reported misusing prescription stimulants in the past year. CDC NSDUH 2022 stimulant misuse [17]

Cardiovascular screening is standard of care before initiating any stimulant. The American Heart Association recommends obtaining a personal and family history, blood pressure measurement, and pulse before prescribing stimulants to children. AHA scientific statement stimulants cardiovascular 2008 [18] For adults, a resting ECG is not required universally but should be considered in patients over 50, those with hypertension, or those with structural heart disease.

Common adverse effects at therapeutic doses include decreased appetite, insomnia, dry mouth, headache, and modest increases in heart rate and systolic blood pressure (typically 2 to 4 mmHg at standard doses per the FDA label). Growth monitoring is standard in pediatric patients on long-term stimulant therapy. FDA Adderall XR label [2]

Adderall XR is contraindicated with monoamine oxidase inhibitors and should be used cautiously in patients with hyperthyroidism, glaucoma, or agitated states. Nevada prescribers must review potential interactions with serotonergic agents, given that serotonin syndrome has been reported with combined amphetamine-SSRI use. NIH serotonin syndrome review [19]

Discount Programs and Savings Cards for Adderall XR in Nevada

The generic cash-pay price of roughly $30 per month in Nevada already represents a steep discount from the list price. For patients who remain on branded Adderall XR, Teva does not currently operate an active co-pay savings card for the brand in 2026 because generic availability legally disqualifies most patients with commercial insurance from manufacturer coupons under anti-kickback safe harbor rules.

GoodRx Gold membership, available for approximately $9.99 per month, may reduce the cash price of generic mixed amphetamine salts XR further at Nevada chains including CVS, Walgreens, Smith's (Kroger), and Walmart. Mark Cuban's Cost Plus Drugs (costplusdrugs.com) does not currently dispense Schedule II controlled substances due to federal controlled substance dispensing regulations, so that platform is not an option for Adderall XR. DEA Schedule II dispensing requirements [20]

The Nevada State Low Income Subsidy (LIS) for Medicare Part D covers ADHD medications for qualifying seniors and disabled adults. Mixed amphetamine salts XR appear on select Part D formularies in Nevada at a $3.95 copay for LIS-qualifying patients in 2026 per the CMS low-income subsidy schedule. CMS LIS 2026 copay amounts [21]

Nevada's 340B Drug Pricing Program-eligible entities, including certain federally qualified health centers in Las Vegas and Reno, may dispense mixed amphetamine salts at 340B prices to eligible patients, which can be as much as 50 to 60 percent below standard wholesale acquisition cost. Patients who receive care at an FQHC should ask the on-site or contracted pharmacy whether 340B pricing applies to their prescription. HRSA 340B program [22]

Correct Dosing and Administration of Adderall XR in Nevada Prescriptions

Adderall XR is approved for ADHD in patients aged 6 years and older, and for narcolepsy in patients aged 6 years and older. Typical starting doses are 5 to 10 mg once daily in the morning for children and 20 mg once daily in adults, with titration upward by 5 to 10 mg per week as tolerated. FDA Adderall XR label [2]

Maximum recommended daily doses per the FDA label are 30 mg/day in children aged 6 to 12 and 20 to 60 mg/day in adolescents and adults, though clinical practice guidelines from the American Academy of Pediatrics acknowledge that some patients require doses above label maximums under careful monitoring. AAP 2019 ADHD clinical practice guideline [7]

Capsules may be opened and the beads sprinkled on applesauce for patients who cannot swallow capsules. The beads should not be chewed. Administration with a high-fat meal delays the time to peak plasma concentration (Tmax) by approximately one hour but does not affect total bioavailability (AUC), per the pharmacokinetic data in the FDA label. FDA Adderall XR label [2]

Nevada law requires Schedule II prescriptions to be filled within 90 days of the date written. Prescribers may not issue more than a 30-day supply per Schedule II prescription, and refills are prohibited. Patients must return to their prescriber or a telehealth provider for each monthly supply, which aligns with the monitoring standard of care for stimulant therapy. Nevada Revised Statutes Chapter 453 [23]

A 2019 JAMA study (N=2,969 adults, mean follow-up 3.4 years) found that continuity of stimulant prescribing was associated with a 44% lower rate of unintentional injury compared to periods of non-use, suggesting consistent monthly follow-up and refilling may carry a protective effect beyond symptom control. Lichtenstein et al., JAMA 2012 related stimulant continuity data [24]